Trial Profile
A randomized, placebo-controlled, double-blind, multicentre trial in patients with symptomatic Heart Failure to evaluate the efficacy of the ARB valsartan.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Jul 2017
Price :
$35
*
At a glance
- Drugs Valsartan (Primary)
- Indications Atrial fibrillation; Heart failure
- Focus Therapeutic Use
- Acronyms Val-HeFT
- Sponsors Novartis Pharmaceuticals Corporation
- 05 Nov 2010 New trial record.